Lorenzo Pellegrini, PhD, Founder and Chief Executive Officer of Palladio Biosciences discusses his company. Palladio Biosciences is a private biotech company and was founded in 2015 to develop transformative medicines for orphan diseases of the kidney.
The company’s first product is lixivaptan and is being re-positioned for the treatment of polycystic kidney disease (PKD). PKD is one of the most common, life-threatening genetic diseases. PKD causes numerous fluid-filled cysts to grow in both kidneys. It is a life-limiting, chronic and progressive disease. PKD is the 4th leading cause of kidney failure and carries a significant financial and emotional burden, affecting entire families.
There is no cure for PKD and no drug has been approved for treatment in the United States.